S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

SLRN ACELYRIN Inc

4.73

0.03 (0.64%)

After Hours

Last Updated: 08:41:12

Delayed by 15 minutes

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

ACELYRIN (NASDAQ:SLRN)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more ACELYRIN Charts.

ACELYRIN (NASDAQ:SLRN)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more ACELYRIN Charts.

ACELYRIN Inc News

Form S-3 - Registration statement under Securities Act of 1933
Thursday 14 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 14 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 14 November 2024 (2 weeks ago) • Edgar (US Regulatory)

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
Thursday 14 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Saturday 9 November 2024 (2 weeks ago) • Edgar (US Regulatory)

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
Thursday 7 November 2024 (3 weeks ago) • GlobeNewswire Inc.

Form 8-K/A - Current report: [Amend]
Tuesday 5 November 2024 (3 weeks ago) • Edgar (US Regulatory)

ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
Wednesday 16 October 2024 (1 month ago) • GlobeNewswire Inc.

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
Thursday 19 September 2024 (2 months ago) • GlobeNewswire Inc.

ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Sur
Tuesday 10 September 2024 (3 months ago) • GlobeNewswire Inc.

ACELYRIN, INC. to Participate in Upcoming Investor Conferences
Thursday 22 August 2024 (3 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 14 August 2024 (3 months ago) • Edgar (US Regulatory)

More ACELYRIN Inc News Articles

Sterling vs AUD

Newcrest Mining

Australian SE All Ordina...

Westpac Banking

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions